Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor

Transfusion. 2014 Dec;54(12):3131-7. doi: 10.1111/trf.12761. Epub 2014 Jun 19.


Background: Compared with growth factor (G) alone, the combination of G with plerixafor (G + P) increases peripheral blood CD34+ count (PB-CD34+) and improves CD34+ collection yield (yCD34+) in multiple myeloma and lymphoma patients undergoing autologous hematopoietic progenitor cell (AHPC) mobilization. It is unknown whether the improved yCD34+ with G + P results entirely from expansion of PB-CD34+ or also from increased intraapheresis CD34+ recruitment and collection efficiency.

Study design and methods: We retrospectively studied 192 patients who underwent AHPC mobilization and collection with G (n = 73) or G + P (n = 119) to compare the adjusted relative efficiency (aRE), the proportion of the circulating CD34+ pool that is captured for each blood volume processed. Additionally, in a prospective cohort of nine patients mobilizing with G and 11 with G + P, PB-CD34+ after leukapheresis allowed calculation of the recruitment coefficient (RC), proportion of the initial CD34+ pool recruited from the marrow into peripheral blood for each blood volume processed.

Results: There was no difference in aRE between G and G + P (0.50 vs. 0.46; p = 0.37) and no substantial decline in aRE with higher blood volumes processed in either group. RC was also not different between G and G + P (median, 0.39 and 0.38, respectively; p = 0.7). Prediction of yCD34+ was determined essentially by PB-CD34+ and not affected independently by plerixafor.

Conclusion: Kinetics of intraapheresis CD34+ recruitment and collection is proportional to PB-CD34+ but not influenced further by plerixafor.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Aged
  • Anti-HIV Agents / administration & dosage*
  • Antigens, CD34*
  • Autografts
  • Benzylamines
  • Blood Component Removal*
  • Cyclams
  • Hematopoietic Stem Cell Mobilization*
  • Hematopoietic Stem Cells*
  • Heterocyclic Compounds / administration & dosage*
  • Humans
  • Lymphoma / therapy
  • Male
  • Middle Aged
  • Multiple Myeloma / therapy
  • Peripheral Blood Stem Cell Transplantation
  • Retrospective Studies


  • Anti-HIV Agents
  • Antigens, CD34
  • Benzylamines
  • Cyclams
  • Heterocyclic Compounds
  • plerixafor